Skip navigation
Use este identificador para citar ou linkar para este item: http://repositorio.unb.br/handle/10482/44874
Arquivos associados a este item:
Não existem arquivos associados a este item.
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorAndrade, Elaine Silva Nascimento-
dc.contributor.authorBrandão, Jurema Guerrieri-
dc.contributor.authorSilva, Juliana Souza da-
dc.contributor.authorCoriolano, Carmelita Ribeiro Filha-
dc.contributor.authorRosa, Patricia Sammarco-
dc.contributor.authorMoraes, Milton Ozório-
dc.contributor.authorFerreira, Cynthia de Oliveira-
dc.contributor.authorGomes, Ciro Martins-
dc.contributor.authorAraújo, Wildo Navegantes de-
dc.date.accessioned2022-09-22T20:07:07Z-
dc.date.available2022-09-22T20:07:07Z-
dc.date.issued2022-04-
dc.identifier.citationANDRADE, Elaine Silva Nascimento et al. Antimicrobial resistance among leprosy patients in Brazil: real-world data based on the national surveillance plan. Antimicrobial Agents and Chemotherapy, v. 66, n. 5, abr. 2022. DOI 10.1128/aac.02170-21. Disponível em: https://journals.asm.org/doi/10.1128/aac.02170-21. Acesso em: 22 set. 2022.pt_BR
dc.identifier.urihttps://repositorio.unb.br/handle/10482/44874-
dc.language.isoInglêspt_BR
dc.rightsAcesso Restritopt_BR
dc.titleAntimicrobial resistance among leprosy patients in Brazil : real-world data based on the national surveillance planpt_BR
dc.typeArtigopt_BR
dc.subject.keywordResistência a drogaspt_BR
dc.subject.keywordHanseníasept_BR
dc.subject.keywordDNApt_BR
dc.identifier.doihttps://doi.org/10.1128/aac.02170-21pt_BR
dc.relation.publisherversionhttps://journals.asm.org/doi/10.1128/aac.02170-21pt_BR
dc.description.abstract1Brazil ranks second among countries for new cases and first for relapse cases of leprosy worldwide. The Mycobacterium leprae Resistance Surveillance Plan was established. We aimed to present the results of a 2-year follow-up of the National Surveillance Plan in Brazil. A cross-sectional study of leprosy cases was performed to investigate antimicrobial resistance (AMR) in Brazil from October 2018 to September 2020. Molecular screening targeting genes related to dapsone (folP1), rifampin (rpoB), and ofloxacin resistance (gyrA) was performed. During the referral period, 63,520 active leprosy patients were registered in Brazil, and 1,183 fulfilled the inclusion criteria for molecular AMR investigation. In total, only 16 (1.4%) patients had genetic polymorphisms associated with AMR. Of these, 8 (50%) had cases of leprosy relapse, 7 (43.8%) had cases of suspected therapeutic failure with standard treatment, and 1 (6.2%) was a case of new leprosy presentation. M. leprae strains with AMR-associated mutations were found for all three genes screened. Isolates from two patients showed simultaneous resistance to dapsone and rifampin, indicating multidrug resistance (MDR). No significant relationship between clinical variables and the presence of AMR was identified. Our study revealed a low frequency of AMR in Brazil. Isolates were resistant mainly to dapsone, and a very low number of isolates were resistant to rifampin, the main bactericidal agent for leprosy, or presented MDR, reinforcing the importance of the standard World Health Organization multidrug therapy. The greater frequency of AMR among relapsed patients supports the need to constantly monitor this group.pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-8066-8283pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-3069-6884pt_BR
dc.description.unidadeFaculdade de Medicina (FM)-
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro simples do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.